收藏切换
Research progress and challenges of the immune adjuvant QS-21
收藏切换
Shu-pei YANG1, 2, Ying-shun XIN1, 2, Bei-bei NI2, Chan LI2, Jian LI2, Da-zhuang WANG2, Jiang-man LIU2, Li-sha HAO2, Chun-lei LI1, 2, *
Acta Pharmaceutica Sinica | 2026, 61(4) : 1051 - 1061
Less
收藏切换
Acta Pharmaceutica Sinica | 2026, 61(4): 1051-1061
• Reviews •
Research progress and challenges of the immune adjuvant QS-21
Full
Shu-pei YANG1, 2, Ying-shun XIN1, 2, Bei-bei NI2, Chan LI2, Jian LI2, Da-zhuang WANG2, Jiang-man LIU2, Li-sha HAO2, Chun-lei LI1, 2, *
Affiliations
  • 1School of Pharmacy, Hebei Medical University, Shijiazhuang 050017, China
  • 2Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., CSPC Pharmaceutical Group, Shijiazhuang 050035, China
Published: 2026-04-12 doi: 10.16438/j.0513-4870.2025-1096
Outline
收藏切换

QS-21 is an immunologically active saponin-based immunostimulant extracted from the bark of the South American soapbark tree (Quillaja saponaria, QS). It consists of four structural domains: Quillaic acid, a trisaccharide side chain, a tetrasaccharide chain, and a pseudodimeric acyl chain. It exists in two isomeric forms, QS-21-Api and QS-21-Xyl, among which the C-4 aldehyde group and the acyl side chain are the key moieties for adjuvant activity. In terms of its immunological mechanism, QS-21 can simultaneously activate Th1/Th2-type immune responses, enhance the cross-presentation of antigens by dendritic cells, and activate the MAPK (mitogen-activated protein kinase) pathway in T cells as well as the NLRP3 (NOD-like receptor protein 3) inflammasome. It exhibits particularly prominent performance in inducing cellular immunity. This article summarizes the currently developed composite adjuvant systems such as AS01, AS02, Matrix-M, AS15, and GLA-LSQ, along with their applications in vaccines including the malaria vaccine Mosquirix and the shingles vaccine Shingrix. Regarding issues such as supply shortages associated with natural extraction, technologies for chemical total synthesis, semi-synthesis, and yeast-based biosynthesis are making gradual breakthroughs, Strategies including some derivatives (such as VSA-1 and TQL1055) also provide references for the development of new vaccines and the prevention and control of infectious diseases as well as immunotherapy.

QS-21  /  immunity  /  composite adjuvant  /  application  /  synthesis
杨树培, 辛英舜, 倪蓓蓓, 李蝉, 李健, 王大壮, 刘姜曼, 郝丽莎, 李春雷. 免疫佐剂QS-21的研究进展与挑战. 药学学报, 2026 , 61 (4) : 1051 -1061 . DOI: 10.16438/j.0513-4870.2025-1096
Shu-pei YANG, Ying-shun XIN, Bei-bei NI, Chan LI, Jian LI, Da-zhuang WANG, Jiang-man LIU, Li-sha HAO, Chun-lei LI. Research progress and challenges of the immune adjuvant QS-21[J]. Acta Pharmaceutica Sinica, 2026 , 61 (4) : 1051 -1061 . DOI: 10.16438/j.0513-4870.2025-1096
Year 2026 volume 61 Issue 4
339
120
Cite this Article
BibTeX
Article Info
doi: 10.16438/j.0513-4870.2025-1096
  • Receive Date:2025-09-15
  • Online Date:2026-09-21
  • Published:2026-04-12
Article Data
Affiliations
History
  • Received:2025-09-15
  • Revised:2025-10-31
Affiliations
    1School of Pharmacy, Hebei Medical University, Shijiazhuang 050017, China
    2Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., CSPC Pharmaceutical Group, Shijiazhuang 050035, China
References
Share
https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2025-1096
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT